| Budget Amount *help |
¥18,720,000 (Direct Cost: ¥14,400,000、Indirect Cost: ¥4,320,000)
Fiscal Year 2013: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
|
|---|
| Research Abstract |
Pancreatic and biliary cancer is still poor prognostic cancer though surgical, chemotherapeutic and radiological treatment is improving. In this research, we vaccinated the highest rank tumor associated antigen WT1 peptide to patients with chemo-refractory pancreatic cancer. Median survival rate of the patients was eight month in a certain condition resulting in the prospective randomized trial. We confirmed that pancreatic adenocarcinoma, neuroendocrine tumors and acinar cell carcinoma expressed WT1 frequently. We also found new molecular targets relevant to the prognosis from the resected specimen.
|
